期刊文献+

FGF-21、MIP-2在特发性肺纤维化中的变化及临床意义 被引量:3

Study of changes and clinical significance of FGF-21 and MIP-2 in idiopathic pulmonary fibrosis
下载PDF
导出
摘要 目的研究成纤维细胞生长因子21(FGF-21)、巨噬细胞炎性蛋白2(MIP-2)在特发性肺纤维化中的变化及其临床意义。方法选取2013年12月-2018年12月海南省人民医院确诊的特发性肺纤维化患者80例,取患者肺纤维化组织为研究对象,取肺旁正常组织作为对照,Western blotting检测FGF-21和MIP-2蛋白的相对表达量,逆转录聚合酶链反应(RT-PCR)检测FGF-21 mRNA和MIP-2 mRNA的表达水平。比较两组FGF-21和MIP-2蛋白和mRNA的表达水平及其与临床病理特征的关系。利用条件Logistic回归分析特发性肺纤维化的相关因素,利用Cox回归分析特发性肺纤维化患者临床预后的相关因素。结果特发性肺纤维化组织FGF-21mRNA、MIP-2 mRNA及其蛋白的表达均较正常组织升高(P<0.05);FGF-21 mRNA和MIP-2 mRNA的表达与患者年龄、性别、吸烟、BMI和病程无关(P>0.05)。条件Logistic回归分析模型结果表明,特发性肺纤维化的发生与FGF-21 mRNA、MIP-2 mRNA呈正相关(P<0.05);Cox回归分析结果显示,FGF-21 mRNA、MIP-2 mRNA的高表达是影响特发性肺纤维化患者临床预后的独立危险因素。结论 FGF-21 mRNA、MIP-2 mRNA的高表达是特发性肺纤维化发生的相关因素,并与临床预后相关。 Objective To investigate the changes and clinical significance of FGF-21 and MIP-2 in idiopathic pulmonary fibrosis.Methods Eighty patients with idiopathic pulmonary fibrosis in our hospital from December 2013 to December 2018 were selected as the research objects.The pulmonary fibrosis tissue of the patients was taken as the research object,and the adjacent normal tissue was taken as the control.The levels of FGF-21 and MIP-2 were determined by Western blotting,while the levels of FGF-21 and MIP-2 mRNA were determined by RT-PCR.The relationship between pathologic feature and FGF-21 mRNA,MIP-2 mRNA between the two groups was compared.The related factors of idiopathic pulmonary fibrosis were analyzed by Logistic Regression analysis.The related factors of clinical prognosis of patients with idiopathic pulmonary fibrosis were analyzed by COX regression analysis.Results The levels of FGF-21 mRNA,MIP-2 mRNA of pulmonary fibrosis tissue were higher than those of normal tissue(P<0.05).There was no relationship between FGF-21 mRNA,MIP-2 mRNA and age,gender,smoking,BMI as well as disease courses(P>0.05).There was positive relationship between idiopathic pulmonary fibrosis and FGF-21 mRNA,MIP-2 mRNA(P<0.05)analyzed by Logistic Regression analysis.The high expression levels of FGF-21 mRNA and MIP-2 mRNA were independent factors affecting the clinical prognosis of patients with idiopathic pulmonary fibrosis analyzed by COX regression analysis.Conclusions The high expression levels of FGF-21 mRNA and MIP-2 mRNA are related factors in the occurrence of idiopathic pulmonary fibrosis,and are associated with clinical prognosis.
作者 丁秀秀 谢甜 黄奕江 Xiu-xiu Ding;Tian Xie;Yi-jiang Huang(Department of Respiratory and Critical Medical,Hainan General Hospital,Haikou,Hainan 570311,china)
出处 《中国现代医学杂志》 CAS 2020年第7期42-47,共6页 China Journal of Modern Medicine
基金 2019年海南省自然科学基金青年基金项目(No:819QN354)。
关键词 特发性肺纤维化 成纤维细胞生长因子21 巨噬细胞炎性蛋白2 idiopathic pulmonary fibrosis fibroblast growth factor 21 macrophage inflammatory protein 2
  • 相关文献

参考文献13

二级参考文献100

  • 1骆仙芳,沈华浩.慢性阻塞性肺疾病与肺血管系统[J].国外医学(呼吸系统分册),2005,25(6):433-435. 被引量:13
  • 2宋建平,刘方州,李伟,李瑞琴,张瑞.金匮肾气丸对肺纤维化大鼠肺组织中肿瘤坏死因子α表达的影响[J].中成药,2006,28(1):78-81. 被引量:13
  • 3李梅,谷淑玲,马腾飞.D-氨基半乳糖致小鼠、大鼠肝损伤模型的实验性研究[J].徐州医学院学报,2007,27(2):86-88. 被引量:26
  • 4陈平.-[J].中华内科杂志,2001,40:232-235.
  • 5Idiopathic pulmonary fibrosis: diagnosis and treatment. International Consensus Statement. American Thoracic Society ( ATS ), and the European Respiratory Society (ERS). Am J Respir Crit Care Med, 2000,161:646-664.
  • 6Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med,2011,183:788-824.
  • 7田德禄.中医内科学(21世纪课程教材)[M].北京:人民卫生出版社,2003:368-378.
  • 8Bando M, Hosono T, Mato N et al. Long-term effieary inhaled N- acelylcysteine patients with idoopathic pulmonary fibrosis [ J ]. In- tern Med ,2010,49 (21) :2289 - 2296.
  • 9Raghu G, Collard HR, Egan JJ, et al. An Official ATS/ERS/JRS/ ALAT statement : idiopathic pulmonary fibrosis : evidence-based guidelines for diagnosis and management [ J ]. Am J Respir Crit Care Med ,2011 ;183 : 788 -824.
  • 10Taniguchi H, Ebina M, Kondoh Y, et al. Pirfenidone Clinical Study Group in Japan. Pirfenidone in Idiopathic Pulmonary Fibrosis: A phase III clinical trial in Japan [ J]. Eur Respir,2010;35:821 - 829.

共引文献487

同被引文献45

引证文献3

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部